Impact of khat (Catha edulis) and oral contraceptive use on telomerase levels and tumor suppressor genes p53 and p21 in normal subjects and breast cancer patients.
Catha edulis
Breast cancer
Khat
Oral contraceptives
P21
P53
Telomerase
Tumor suppresser gene
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
received:
20
04
2024
accepted:
10
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
epublish
Résumé
This study aimed to evaluate the effects of oral contraceptive (OC) use, khat chewing, and their combined effect on telomerase level and tumor suppressor genes, p53 and p21 in breast cancer (BC) patients and normal volunteers. 140 Yemeni women aged 25-40 years old enrolled, 60 newly diagnosed pretreated BC patients, and 80 control subjects. Venous blood (5 ml) was collected and the results showed BC patients to have significantly raised levels of telomerase, p53, and p21 compared to the control group. The use of OCs significantly raised telomerase in control group with no effect in BC patients; whereas p53 and p21 were significantly increased in BC patients. On the other hand, khat chewing significantly increased p53 in controls and BC patients, whereas p21 was significantly raised in BC patients. The combined use of OCs and khat chewing significantly increased telomerase and p53 in control group, and significantly increased p53 and p21 in BC patients. Telomerase was shown to be a risk factor (OR 4.4) for BC, and the use of OCs was a high-risk factor for increasing telomerase (OR 27.8) in normal subjects. In contrast, khat chewing was shown to be protective (OR 0.142), and the combined use of OCs and khat chewing decreased the risk factor of telomerase from OR 27.8 to 2.1.
Identifiants
pubmed: 39013992
doi: 10.1038/s41598-024-67355-5
pii: 10.1038/s41598-024-67355-5
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Tumor Suppressor Protein p53
0
Cyclin-Dependent Kinase Inhibitor p21
0
Contraceptives, Oral
0
TP53 protein, human
0
CDKN1A protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16365Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 73(1), 209–249 (2021).
doi: 10.3322/caac.21660
Lei, S. et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 41, 1183–1194 (2021).
doi: 10.1002/cac2.12207
Arnold, M. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66, 15–23 (2022).
pubmed: 36084384
pmcid: 9465273
doi: 10.1016/j.breast.2022.08.010
Bardaweel, S. K., Akour, A. A., Al-Muhaissen, S., AlSalamat, H. A. & Ammar, K. Oral contraceptive and breast cancer: Do benefits outweigh the risks? A case-control study from Jordan. BMC Women Health 19, 1–7 (2019).
doi: 10.1186/s12905-019-0770-x
Baranska, A. et al. Oral contraceptive use and breast cancer risk assessment: A systematic review and meta-analysis of case-control studies, 2009–2020. Cancers 13(22), 5654 (2021).
pubmed: 34830807
pmcid: 8616467
doi: 10.3390/cancers13225654
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13(11), 1141–1151 (2012).
pmcid: 3488186
doi: 10.1016/S1470-2045(12)70425-4
Britt, K. L., Cuzick, J. & Phillips, K. A. Key steps for effective breast cancer prevention. Nat. Rev. Cancer 20, 417–436 (2020).
pubmed: 32528185
doi: 10.1038/s41568-020-0266-x
Kuzhan, A. & Adli, M. The effect of socio–economic–cultural factors on breast cancer. J. Breast Health 11(1), 17–21 (2015).
pubmed: 28331684
pmcid: 5351528
doi: 10.5152/tjbh.2014.2293
Lee, K., Kruper, L., Dieli-Conwright, C. M. & Mortimer, J. E. The impact of obesity on breast cancer diagnosis and treatment. Curr. Oncol. Rep. https://doi.org/10.1007/s11912-019-0787-1 (2019).
doi: 10.1007/s11912-019-0787-1
pubmed: 31502008
pmcid: 6733832
Rizzo, A. et al. Immune-based combinations for metastatic triple-negative breast cancer in clinical trials: Current knowledge and therapeutic prospects. Expert Opin. Investig. Drug 31(6), 557–565 (2022).
doi: 10.1080/13543784.2022.2009456
Gadaleta-Caldarola, G. et al. Safety evaluation of datopotamab deruxtecan for triple-negative breast cancer: A meta-analysis. Cancer Treat. Res. Commun. 37, 100775 (2023).
pubmed: 37956525
doi: 10.1016/j.ctarc.2023.100775
Caputo, R. et al. Sacituzumab govitecan for the treatment of advanced triple-negative breast cancer patients: A multi-center real-world analysis. Front. Oncol. https://doi.org/10.3389/fonc.2024.1362641 (2024).
doi: 10.3389/fonc.2024.1362641
pubmed: 38595817
pmcid: 11002149
Begam, A. J., Jubie, S. & Nanjan, M. J. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorg. Chem. 71, 257–274 (2017).
doi: 10.1016/j.bioorg.2017.02.011
Endogenous Hormones and Breast Cancer Collaborative Group. Sex hormones and breast cancer risk in premenopausal women: Collaborative reanalysis of seven prospective studies. Lancet Oncol. 14(10), 1009–1019 (2013).
pmcid: 4056766
doi: 10.1016/S1470-2045(13)70301-2
Kahlenborn, C., Modugno, F., Potter, D. M. & Severs, W. B. Oral contraceptive use as a risk factor for premenopausal breast cancer: A meta-analysis. Mayo Clin. Proc. 81(10), 1290–1302 (2006).
pubmed: 17036554
doi: 10.4065/81.10.1290
Zhu, H., Lei, X., Feng, J. & Wang, Y. Oral contraceptive use and risk of breast cancer: A meta-analysis of prospective cohort studies. Eur. J. Contracept. Reprod. Health Care 17(6), 402–414 (2012).
pubmed: 23061743
doi: 10.3109/13625187.2012.715357
Del Pup, L., Codacci-Pisanelli, G. & Peccatori, F. Breast cancer risk of hormonal contraception: Counselling considering new evidence. Crit. Rev. Oncol/Hematol. 137, 123–130 (2019).
pubmed: 31014508
doi: 10.1016/j.critrevonc.2019.03.001
Beaber, E. F. et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res. 74(15), 4078–4089 (2014).
pubmed: 25085875
pmcid: 4154499
doi: 10.1158/0008-5472.CAN-13-3400
Bethea, T. N. et al. A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium. Breast Cancer Res. https://doi.org/10.1186/s13058-015-0535-x (2015).
doi: 10.1186/s13058-015-0535-x
pubmed: 25849024
pmcid: 4358874
Mørch, L. S. et al. Contemporary hormonal contraception and the risk of breast cancer. N. Engl. J. Med. 377, 2228–2239 (2017).
pubmed: 29211679
doi: 10.1056/NEJMoa1700732
Kanadys, W. et al. Use of oral contraceptives as a potential risk factor for breast cancer: A systematic review and meta-analysis of case-control studies up to 2010. Int. J. Environ. Res. Public Health 18(9), 4638 (2021).
pubmed: 33925599
pmcid: 8123798
doi: 10.3390/ijerph18094638
Urban, M. et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: Case-control study. PLoS Med. 9(3), e1001182 (2012).
pubmed: 22412354
pmcid: 3295825
doi: 10.1371/journal.pmed.1001182
Hannaford, P. C. et al. Cancer risk among users of oral contraceptives: Cohort data from the Royal College of general practitioner’s oral contraception study. BMJ 335, 651 (2007).
pubmed: 17855280
pmcid: 1995533
doi: 10.1136/bmj.39289.649410.55
Marchbanks, P. A. et al. Oral contraceptive formulation and risk of breast cancer. Contraception 85(4), 342–350 (2012).
pubmed: 22067757
doi: 10.1016/j.contraception.2011.08.007
Vessey, M. & Yeates, D. Oral contraceptive use and cancer: Final report from the Oxford-family planning association contraceptive study. Contraception 88(6), 678–683 (2013).
pubmed: 24090961
doi: 10.1016/j.contraception.2013.08.008
Busund, M. et al. Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian women and cancer study. Int. J. Cancer 142(11), 2293–2302 (2018).
pubmed: 29349773
pmcid: 5893363
doi: 10.1002/ijc.31266
al’Absi, M. et al. Concurrent tobacco and khat use is associated with blunted cardiovascular stress response and enhanced negative mood: A cross-sectional investigation. Hum. Psychopharmacol. 29(4), 307–315 (2014).
pubmed: 24706595
pmcid: 5763500
doi: 10.1002/hup.2403
Al-Habori, M. The potential adverse effects of habitual use of Catha edulis (khat). Expert Opin. Drug Saf. 4(6), 1129–1138 (2005).
doi: 10.1517/14740338.4.6.1145
Al-Motarreb, A., Al-Habori, M. & Broadley, K. J. Khat chewing, cardiovascular diseases and other internal medical problems: The current situation and directions for future research. J. Ethnopharmacol. 132(3), 540–548 (2010).
pubmed: 20621179
doi: 10.1016/j.jep.2010.07.001
Dimba, E. A. et al. Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukemia cells. Br. J. Cancer 91, 1726–1734 (2004).
pubmed: 15477863
pmcid: 2409956
doi: 10.1038/sj.bjc.6602197
Bredholt, T. et al. Distinct single-cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacol. Toxicol. https://doi.org/10.1186/2050-6511-14-35 (2013).
doi: 10.1186/2050-6511-14-35
pubmed: 23845085
pmcid: 3733921
Bredholt, T. et al. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIP, Mcl-l, procaspase-8 and mitochondrial function in acute myeloid leukemia. Mol. Cancer https://doi.org/10.1186/1476-4598-8-101 (2009).
doi: 10.1186/1476-4598-8-101
pubmed: 19912650
pmcid: 2781802
Lukandu, O. M., Costea, D. E., Neppelberg, E., Johannessen, A. C. & Vintermyr, O. K. Khat (Catha edulis) induces reactive oxygen species and apoptosis in normal human oral keratinocytes and fibroblasts. Toxicol. Sci. 103(2), 311–324 (2008).
pubmed: 18310640
doi: 10.1093/toxsci/kfn044
Lukandu, O. M. et al. Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. Eur. J. Oral Sci. 116(1), 23–30 (2008).
pubmed: 18186728
doi: 10.1111/j.1600-0722.2007.00508.x
Abou-Elhamd, A. S. et al. Unraveling the Catha edulis extract effects on the cellular and molecular signaling in SKOV3 cells. Front. Pharmacol. https://doi.org/10.3389/fphar.2021.666885 (2021).
doi: 10.3389/fphar.2021.666885
pubmed: 34040530
pmcid: 8141790
Abid, M. D. et al. Khat (Catha edulis) generates reactive oxygen species and promotes hepatic cell apoptosis via MAPK activation. Int. J. Mol. Med. 32, 389–395 (2013).
pubmed: 23708648
doi: 10.3892/ijmm.2013.1394
Shay, J. W. & Wright, W. E. Telomeres and telomerase: Three decades of progress. Nat. Rev. Genet. 20(5), 299–309 (2019).
pubmed: 30760854
doi: 10.1038/s41576-019-0099-1
Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011–2015 (1994).
pubmed: 7605428
doi: 10.1126/science.7605428
Herbert, B.-S., Wright, W. E. & Shay, J. W. Telomerase and breast cancer. Breast Cancer Res. https://doi.org/10.1186/bcr288 (2001).
doi: 10.1186/bcr288
pubmed: 11305948
pmcid: 3300533
Kalogeraki, A. et al. Telomerase activity as a marker of invasive ductal breast carcinomas on FNABs and relationship to other prognostic variables. Anticancer Res. 25(3B), 1927–1930 (2005).
pubmed: 16158927
Lu, L. et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res. https://doi.org/10.1186/bcr2893 (2011).
doi: 10.1186/bcr2893
pubmed: 21645396
pmcid: 3218945
Shpitz, B. et al. Telomerase activity in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 58, 65–69 (1999).
pubmed: 10634519
doi: 10.1023/A:1006394209922
Murillo-Ortiz, B., Astudillo-De, H., Castillo-Medina, S., Malacara, J. M. & Benitez-Bribiesca, L. Telomerase activity, estrogen receptors (α, β), Bcl-2 expression in human breast cancer and treatment response. BMC Cancer https://doi.org/10.1186/1471-2407-6-206 (2006).
doi: 10.1186/1471-2407-6-206
pubmed: 16911782
pmcid: 1562436
Simsek, B. C., Turk, B. A., Ozen, F., Tuzcu, M. & Kanter, M. Investigation of telomerase activity and apoptosis on invasive ductal carcinoma of the breast using immunohistochemical and western blot methods. Eur. Rev. Med. Pharmacol. Sci. 19, 3089–3099 (2015).
pubmed: 26367733
Loveday, R. L., Greenman, J., Drew, P. J., Monson, J. R. & Kerin, M. J. Genetic changes associated with telomerase activity in breast cancer. Int. J. Cancer 84(5), 516–520 (1999).
pubmed: 10502730
doi: 10.1002/(SICI)1097-0215(19991022)84:5<516::AID-IJC12>3.0.CO;2-Y
Kanaya, T. et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res. 6(4), 1239–1247 (2000).
pubmed: 10778946
Stampfer, M. R. et al. Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines. Oncogene 22, 5238–5251 (2003).
pubmed: 12917625
doi: 10.1038/sj.onc.1206667
Bieging, K. T., Mello, S. S. & Attardi, L. D. Unraveling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359–370 (2014).
pubmed: 24739573
pmcid: 4049238
doi: 10.1038/nrc3711
Abbas, T. & Dutta, A. p21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer 9, 400–414 (2009).
pubmed: 19440234
pmcid: 2722839
doi: 10.1038/nrc2657
El-Deiry, W. S. p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res. 76(18), 5189–5191 (2016).
pubmed: 27635040
pmcid: 5028108
doi: 10.1158/0008-5472.CAN-16-2055
Hiyama, E. et al. Telomerase activity in human breast tumors. J. Natl. Cancer Inst. 88(2), 116–122 (1996).
pubmed: 8537972
doi: 10.1093/jnci/88.2.116
Roos, G. et al. Telomerase activity in relation to p53 status and clinicopathological parameters in breast cancer. Int. J. Cancer 79(4), 343–348 (1998).
pubmed: 9699524
doi: 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V
Swellam, M., Smail, M., Eissa, S., Hamdy, M. & Mokhtar, N. Emerging role of p53, Bcl-2 and telomerase activity in Egyptian breast cancer patients. IUBMB Life 56(8), 483–490 (2004).
pubmed: 15545228
doi: 10.1080/15216540400010834
Winnikow, E. P. et al. Accuracy of telomerase in estimating breast cancer risk: A systematic review and meta-analysis. Breast 21(1), 1–7 (2012).
pubmed: 21911295
doi: 10.1016/j.breast.2011.08.136
Aviv, A., Anderson, J. J. & Shay, J. W. Mutations, cancer and the telomere length paradox. Trends Cancer 3(4), 253–258 (2017).
pubmed: 28718437
pmcid: 5903276
doi: 10.1016/j.trecan.2017.02.005
Zhang, X. et al. The association of telomere length in peripheral blood cells with cancer risk: A systematic review and meta-analysis of prospective studies. Cancer Epidemiol. Biomark. Prev. 26(9), 1381–1390 (2017).
doi: 10.1158/1055-9965.EPI-16-0968
Samavat, H. et al. Association between prediagnostic leukocyte telomere length and breast cancer risk: The Singapore Chinese health study. Breast Cancer Res. https://doi.org/10.1186/s13058-019-1133-0 (2019).
doi: 10.1186/s13058-019-1133-0
pubmed: 30995937
pmcid: 6471852
Svenson, U. et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res. 68(10), 3618–3623 (2008).
pubmed: 18483243
doi: 10.1158/0008-5472.CAN-07-6497
Gramatges, M. M., Telli, M. L., Balise, R. & Ford, J. M. Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Cancer Epidemiol. Biomark. Prev. 19(2), 605–613 (2010).
doi: 10.1158/1055-9965.EPI-09-0896
Rode, L., Nordestgaard, B. G. & Bojesen, S. E. Long telomeres and cancer risk among 95 568 individuals from the general population. Int. J. Epidemiol. 45(5), 1634–1643 (2016).
pubmed: 27498151
doi: 10.1093/ije/dyw179
Shen, J. et al. Telomere length, oxidative damage, antioxidants, and breast cancer risk. Int. J. Cancer 124(7), 1637–1643 (2009).
pubmed: 19089916
pmcid: 2727686
doi: 10.1002/ijc.24105
Heaphy, C. M. & Meeker, A. K. The potential utility of telomere-related markers for cancer diagnosis. J. Cell. Mol. Med. 15(6), 1227–1238 (2011).
pubmed: 21352473
pmcid: 4373325
doi: 10.1111/j.1582-4934.2011.01284.x
Gay-Bellile, M. et al. ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis. J. Pathol. Clin. Res. 2(4), 234–246 (2016).
pubmed: 27785368
pmcid: 5068194
doi: 10.1002/cjp2.52
Hoos, A. et al. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int. J. Cancer 79, 8–12 (1998).
pubmed: 9495350
doi: 10.1002/(SICI)1097-0215(19980220)79:1<8::AID-IJC2>3.0.CO;2-5
Umbricht, C. B. et al. Telomerase activity in ductal carcinoma in situ and invasive breast cancer. Oncogene 18, 3407–3414 (1999).
pubmed: 10362362
doi: 10.1038/sj.onc.1202714
Kulić, A. et al. Telomerase activity in breast cancer patients: Association with poor prognosis and more aggressive phenotype. Med. Oncol. 33, 23 (2016).
pubmed: 26833480
doi: 10.1007/s12032-016-0736-x
Gursan, N., Karakok, M., Sari, I. & Gursan, M. S. The relationship between the expression of p53/ Bcl-2 and histopathological criteria in breast invasive ductal carcinomas. Int. J. Clin. Pract. 55(9), 589–590 (2001).
pubmed: 11770353
doi: 10.1111/j.1742-1241.2001.tb11134.x
Jassim, M. M., Rasool, K. H. & Mahmood, M. M. p53, p21, and cyclin d1 protein expression patterns in patients with breast cancer. Vet. World 14(10), 2833–2838 (2021).
pubmed: 34903946
pmcid: 8654745
doi: 10.14202/vetworld.2021.2833-2838
Li, J. P. et al. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine 98(18), e15449 (2019).
pubmed: 31045815
pmcid: 6504250
doi: 10.1097/MD.0000000000015449
Sadia, H. et al. Determination of expression profile of p53 gene in different grades of breast cancer tissues by real-time PCR. Afr. Health Sci. 20(3), 1273–1282 (2020).
pubmed: 33402975
pmcid: 7751535
doi: 10.4314/ahs.v20i3.32
Balogh, G. A. et al. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Int. J. Oncol. 28(4), 995–1002 (2006).
pubmed: 16525651
Vousden, K. H. & Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275–283 (2007).
pubmed: 17380161
doi: 10.1038/nrm2147
Jin, M. S. et al. New insight on the biological role of p53 protein as a tumor suppressor: Re-evaluation of its clinical significance in triple-negative breast cancer. Tumor Biol. 37, 11017–11024 (2016).
doi: 10.1007/s13277-016-4990-5
Xiong, Y. et al. P21 is a universal inhibitor of cyclin kinase. Nature 366, 701–704 (1993).
pubmed: 8259214
doi: 10.1038/366701a0
Wei, C.-Y. et al. Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance. Int. J. Clin. Exp. Pathol. 8(11), 14619–14629 (2015).
pubmed: 26823785
pmcid: 4713571
Kyo, S. et al. Estrogen activates telomerase. Cancer Res. 59, 5917–5921 (1999).
pubmed: 10606235
Kimura, A. et al. Induction of hTERT expression and phosphorylation by estrogen via akt cascade in human ovarian cancer cell lines. Oncogene 23, 4505–4515 (2004).
pubmed: 15048073
doi: 10.1038/sj.onc.1207582
Calado, R. T. et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 114(11), 2236–2243 (2009).
pubmed: 19561322
pmcid: 2745844
doi: 10.1182/blood-2008-09-178871
Sehl, M. E., Henry, J. E., Storniolo, A. M., Horvath, S. & Ganz, P. A. The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue. Breast Cancer https://doi.org/10.1038/s41523-022-00410-4 (2022).
doi: 10.1038/s41523-022-00410-4
pubmed: 35418123
pmcid: 9007943
Shin, Y.-A. & Lee, K.-Y. Low estrogen levels and obesity are associated with shorter telomere lengths in pre- and post-menopausal women. J. Exerc. Rehabil. 12(3), 238–246 (2016).
pubmed: 27419121
pmcid: 4934970
doi: 10.12965/jer.1632584.292
Fagan, E. et al. Telomere length is longer in women with late maternal age. Menopause 24(5), 497–501 (2017).
pubmed: 27922939
pmcid: 5403597
doi: 10.1097/GME.0000000000000795
Russo, J. & Russo, I. H. The role of estrogen in the initiation of breast cancer. J. Steroid Biochem. Mol. Biol. 102(1–5), 89–96 (2006).
pubmed: 17113977
pmcid: 1832080
doi: 10.1016/j.jsbmb.2006.09.004
Artandi, S. E. Complex roles for telomeres and telomerase in breast carcinogenesis. Breast Cancer Res. 5, 37–41 (2003).
pubmed: 12559044
doi: 10.1186/bcr553
Zhang, J., Tu, Y. & Smith-Schneider, S. Activation of p53, inhibition of telomerase activity and induction of estrogen receptor beta are associated with the anti-growth effects of combination of ovarian hormones and retinoids in immortalized human mammary epithelial cells. Cancer Cell Int. 5, 6 (2005).
pubmed: 15755327
pmcid: 555559
doi: 10.1186/1475-2867-5-6
Zhou, C. et al. Estrogen induction of telomerase activity through regulation of the mitogen-activated protein kinase (MAPK) dependent pathway in human endometrial cancer cells. PLoS One 8(2), e55730 (2013).
pubmed: 23409030
pmcid: 3567109
doi: 10.1371/journal.pone.0055730
Wang, Z. et al. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 60(19), 5376–5381 (2000).
pubmed: 11034074
Mokbel, K. et al. The association between telomerase activity and hormone receptor status and p53 expression in breast cancer. Int. J. Surg. Investig. 1(6), 509–516 (2000).
pubmed: 11729859
Dunphy, K. A., Blackburn, A. C., Yan, H., O’Connell, L. R. & Jerry, D. J. Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/− mice. Breast Cancer Res. 10, R43 (2008).
pubmed: 18471300
pmcid: 2481490
doi: 10.1186/bcr2094
Becker, K. A. et al. Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-beta-dependent pathways. Oncogene 24, 6345–6353 (2005).
pubmed: 15940247
doi: 10.1038/sj.onc.1208787
Bu, S.-Z. et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79(10), 1944–1950 (1997).
pubmed: 9149021
doi: 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V
Sivaraman, L., Conneely, O. M., Medina, D. & O’Malley, B. W. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc. Natl. Acad. Sci. 98(22), 12379–12384 (2001).
pubmed: 11606748
pmcid: 60062
doi: 10.1073/pnas.221459098
Lukandu, O. M., Neppelberg, E., Vintermyr, O. K., Johannessen, A. C. & Costea, D. E. Khat alters the phenotype of in vitro-reconstructed human oral mucosa. J. Dent. Res. 89(3), 270–275 (2010).
pubmed: 20044580
doi: 10.1177/0022034509354980
Onyango, T. B. et al. A comparison of p53 isoform profiles and apoptosis induced by camptothecin or a herbal Khat extract (Catha edulis (Vahl) Forssk ex Endl) in leukemic cell lines: Exploring cellular responses in therapy development. Cancers 12(12), 3596 (2020).
pubmed: 33271840
pmcid: 7760143
doi: 10.3390/cancers12123596
Vousden, K. H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 1602(1), 47–59 (2002).
pubmed: 11960694
Al-Zubairi, A., Ismail, P., Pei, C. P. & Rahmat, A. Genotoxic effect of Catha edulis (khat) crude extract after sub-chronic administration in rats. Environ. Toxicol. Pharmacol. 25(3), 298–303 (2008).
pubmed: 21783866
doi: 10.1016/j.etap.2007.10.032
Appella, E. & Anderson, C. W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268(10), 2764–2772 (2001).
pubmed: 11358490
doi: 10.1046/j.1432-1327.2001.02225.x
Campisi, J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120(4), 513–522 (2005).
pubmed: 15734683
doi: 10.1016/j.cell.2005.02.003
Weinberg, W. C. & Denning, M. F. P21Waf1 control of epithelial cell cycle and cell fate. Crit. Rev. Oral Biol. Med. 13(6), 453–464 (2002).
pubmed: 12499239
doi: 10.1177/154411130201300603
Zhang, J. et al. Natural products and derivatives for breast cancer treatment: From drug discovery to molecular mechanism. Phytomedicine 129, 155600 (2024).
pubmed: 38614043
doi: 10.1016/j.phymed.2024.155600
Andrijauskaite, K. & Wargovich, M. J. Role of natural products in breast cancer-related symptomology: Targeting chronic inflammation. Semin. Cancer Biol. 80, 370–378 (2022).
pubmed: 32891720
doi: 10.1016/j.semcancer.2020.08.011